Methods for inhibiting HIV-1 envelope glycoprotein-medicated membrane fusion
View Patent ↗This invention provides agents determined to be capable of inhibiting the fusion of a macrophage-tropic primary isolate of HIV-1 to a CD4 + cell and agents determined to be capable of inhibiting the fusion of a T cell-tropic isolate of HIV-1 to a CD4 + cell. This invention also provides methods to identify such agents. This invention further provides methods of inhibiting fusion of a macrophage-tropic primary isolate of HIV-1 with a CD+ cell and methods of inhibiting fusion of a T cell-tropic isolate of HIV-1 with a CD4 + cell susceptible to infection by a T cell-tropic isolate of HIV-1.
1. A method of inhibiting fusion of an HIV-1 envelope glycoprotein+ cell with a CD4+ cell that fuses with such HIV-1 envelope glycoprotein+ cell, which comprises contacting the CD4+ cell with an anti-PM1 monoclonal antibody that (1) significantly inhibits macrophage-tropic HIV-1 envelope glycoprotein mediated membrane fusion of HeLa-env JR-FL with a CD4+ PM1 cell, and (2) does not significantly inhibit T cell-tropic HIV-1 envelope glycoprotein mediated membrane fusion of HeLa-env LAI with a HeLa-CD4+ cell, so as to thereby inhibit fusion of the HIV-1 envelope glycoprotein+ cell with the CD4 + cell.
2. The method of claim 1 , wherein the anti-PM1 monoclonal antibody is a chimeric antibody.
3. The method of claim 1 , wherein the anti-PM1 monoclonal antibody is a synthetic antibody.
4. The method of claim 1 , wherein the anti-PM1 monoclonal antibody is an antigen binding fragment of an antibody.